RT Journal Article
SR Electronic
A1 Misra-Press, Anita
T1 ALTER0302
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 16
OP 16
DO 10.1177/1559897715588063
UL http://mdc.sagepub.com/content/15/8/16.1.abstract
AB ALTER0302, a randomized double-blind controlled phase 2 trial, examined the efficacy and safety of anlotinib, a multitargeted tyrosine kinase inhibitor, as third-line therapy for Chinese patients with advanced non–small cell lung cancer. Progression-free survival and objective response rates were increased in all subgroups of patients treated with anlotinib with no associated serious adverse events.